Critical role for IL-1β in DNA damageinduced mucositis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 6, 2014, Pages

  Kanarek, Naama ^a   Grivennikov, Sergei I ^b   Leshets, Michael ^a   Lasry, Audrey ^a   Alkalay, Irit ^a   Horwitz, Elad ^a   Shaul, Yoav D ^c,d,e   Stachler, Matthew ^f   Voronov, Elena ^g   Apte, Ron N ^g   Pagano, Michele ^h   Pikarsky, Eli ^a   Karin, Michael ^a   Ghosh, Sankar ⁱ   Ben Neriah, Yinon ^a  

^a HEBREW UNIVERSITY   (Israel)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^h NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

Anakinra; Anti IL 1 preventive therapy; Cytotoxic side effects; Graft vs. host disease; Gut immunity

Indexed keywords

ANAKINRA; ANTI-IL-1 PREVENTIVE THERAPY; CYTOTOXIC SIDE EFFECTS; GRAFT-VS.-HOST DISEASE; GUT IMMUNITY;

ANIMALS; BASE SEQUENCE; BETA-TRANSDUCIN REPEAT-CONTAINING PROTEINS; DNA DAMAGE; DNA PRIMERS; INTERLEUKIN-1BETA; MALE; MICE; MICE, KNOCKOUT; MITOSIS; MUCOSITIS; NF-KAPPA B; POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84893862941     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1322691111     Document Type: Article

References (46)

1. Frescas D, Pagano M (2008) Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: Tipping the scales of cancer. Nat Rev Cancer 8(6):438-449.
2. Kanarek N, et al. (2010) Spermatogenesis rescue in a mouse deficient for the ubiquitin ligase SCFbeta-TrCP by single substrate depletion. Genes Dev 24(5):470-477.
3. Adams J (2002) Proteasome inhibition: A novel approach to cancer therapy. Trends Mol Med 8(4, suppl):S49-S54.
4. Fuchs SY, Spiegelman VS, Kumar KG (2004) The many faces of beta-TrCP E3 ubiquitin ligases: Reflections in the magic mirror of cancer. Oncogene 23(11):2028-2036.
5. Kanarek N, Ben-Neriah Y (2012) Regulation of NF-kappaB by ubiquitination and degradation of the IkappaBs. Immunol Rev 246(1):77-94.
6. Jiang J, Struhl G (1998) Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb. Nature 391(6666):493-496.
7. Yaron A, et al. (1998) Identification of the receptor component of the IkappaBalphaubiquitin ligase. Nature 396(6711):590-594.
8. Busino L, et al. (2003) Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage. Nature 426(6962):87-91.
9. Watanabe N, et al. (2004) M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFbeta-TrCP. Proc Natl Acad Sci USA 101(13):4419-4424.
10. Guardavaccaro D, et al. (2003) Control of meiotic and mitotic progression by the F box protein beta-Trcp1 in vivo. Dev Cell 4(6):799-812.
11. Seki A, et al. (2008) Plk1-and beta-TrCP-dependent degradation of Bora controls mitotic progression. J Cell Biol 181(1):65-78.
12. Mamely I, et al. (2006) Polo-like kinase-1 controls proteasome-dependent degradation of Claspin during checkpoint recovery. Curr Biol 16(19):1950-1955.
13. Fuchs SY, Chen A, Xiong Y, Pan ZQ, Ronai Z (1999) HOS, a human homolog of Slimb, forms an SCF complex with Skp1 and Cullin1 and targets the phosphorylationdependent degradation of IkappaB and beta-catenin. Oncogene 18(12):2039-2046.
14. Fleischmann RM, et al. (2006) Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 65(8):1006-1012.
15. el Marjou F, et al. (2004) Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. Genesis 39(3):186-193.
16. Nenci A, et al. (2007) Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 446(7135):557-561.
17. Schulzke JD, et al. (2009) Epithelial tight junctions in intestinal inflammation. Ann N Y Acad Sci 1165:294-300.
18. Mankertz J, Schulzke JD (2007) Altered permeability in inflammatory bowel disease: Pathophysiology and clinical implications. Curr Opin Gastroenterol 23(4):379-383.
19. Yoshikawa H, Takada K, Muranishi S (1984) Molecular weight dependence of permselectivity to rat small intestinal blood-lymph barrier for exogenous macromolecules absorbed from lumen. J Pharmacobiodyn 7(1):1-6.
20. Turner JR (2006) Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application. Am J Pathol 169(6):1901-1909.
21. Cohen I, et al. (2010) Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. Proc Natl Acad Sci USA 107(6):2574-2579.
22. Berda-Haddad Y, et al. (2011) Sterile inflammation of endothelial cell-derived apoptotic bodies is mediated by interleukin-1α. Proc Natl Acad Sci USA 108(51): 20684-20689.
23. Al-Sadi RM, Ma TY (2007) IL-1beta causes an increase in intestinal epithelial tight junction permeability. J Immunol 178(7):4641-4649.
24. Greten FR, et al. (2007) NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell 130(5):918-931.
25. Egan LJ, et al. (2004) IκB-kinaseβ-dependent NF-κB activation provides radioprotection to the intestinal epithelium. Proc Natl Acad Sci USA 101(8):2452-2457.
26. Sultani M, Stringer AM, Bowen JM, Gibson RJ (2012) Anti-inflammatory cytokines: Important immunoregulatory factors contributing to chemotherapy-induced gastrointestinal mucositis. Chemother Res Pract 2012:490804.
27. Rodríguez-Caballero A, et al. (2012) Cancer treatment-induced oral mucositis: A critical review. Int J Oral Maxillofac Surg 41(2):225-238.
28. Logan RM, et al. (2007) The role of pro-inflammatory cytokines in cancer treatmentinduced alimentary tract mucositis: Pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev 33(5):448-460.
29. Antin JH, et al. (1994) Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 84(4):1342-1348.
30. Ong ZY, et al. (2010) Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. Radiat Oncol 5:22.
31. Chen LW, et al. (2003) The two faces of IKK and NF-kappaB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemiareperfusion. Nat Med 9(5):575-581.
32. Jung C, et al. (2012) Yersinia pseudotuberculosis disrupts intestinal barrier integrity through hematopoietic TLR-2 signaling. J Clin Invest 122(6):2239-2251.
33. Dinarello CA (2011) A clinical perspective of IL-1β as the gatekeeper of inflammation. Eur J Immunol 41(5):1203-1217.
34. Asquith M, Powrie F (2010) An innately dangerous balancing act: Intestinal homeostasis, inflammation, and colitis-associated cancer. J Exp Med 207(8):1573-1577.
35. Bersudsky M, et al. (2013) Non-redundant properties of IL-1α and IL-1β during acute colon inflammation in mice. Gut, 10.1136/gutjnl-2012- 303329.
36. Elinav E, Henao-Mejia J, Flavell RA (2013) Integrative inflammasome activity in the regulation of intestinal mucosal immune responses. Mucosal Immunol 6(1):4-13.
37. Apte RN, et al. (2006) The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 25(3):387-408.
38. Krelin Y, et al. (2007) Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res 67(3): 1062-1071.
39. Coccia M, et al. (2012) IL-1β mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4(+) Th17 cells. J Exp Med 209(9):1595-1609.
40. Johansson JE, Ekman T (2007) Gut toxicity during hemopoietic stem cell transplantation may predict acute graft-versus-host disease severity in patients. Dig Dis Sci 52(9):2340-2345.
41. Morganti-Kossmann MC, Rancan M, Stahel PF, Kossmann T (2002) Inflammatory response in acute traumatic brain injury: A double-edged sword. Curr Opin Crit Care 8(2):101-105.
42. Mitroulis I, Skendros P, Ritis K (2010) Targeting IL-1beta in disease; the expanding role of NLRP3 inflammasome. Eur J Intern Med 21(3):157-163.
43. Li X, Akhtar S, Choudhry MA (2012) Alteration in intestine tight junction protein phosphorylation and apoptosis is associated with increase in IL-18 levels following alcohol intoxication and burn injury. Biochim Biophys Acta 1822(2):196-203.
44. Greten FR, et al. (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118(3):285-296.
45. Miyazaki S, et al. (2001) Development of systemic bacteraemia after oral inoculation of vancomycin-resistant enterococci in mice. J Med Microbiol 50(8):695-701.
46. Shchors K, et al. (2006) The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta. Genes Dev 20(18):2527-2538.